🩸 Facts about Diffuse Large B-Cell Lymphoma:
EPCORE NHL-2, bispecific + ADC combinations, ECHELON-3, polatuzumab vedotin, and loncastuximab tesirine, including key trial results and treatment advances in relapsed/refractory disease.
#DLBCL #DiffuseLargeBCellLymphoma #Lymphoma #HemeOnc #MedEd
🩸 Facts about Diffuse Large B-Cell Lymphoma: EPCORE NHL-2, bispecific + ADC combinations, ECHELON-3, polatuzumab vedotin, and loncastuximab tesirine, including key trial results and treatment advances in relapsed/refractory disease. #DLBCL #DiffuseLargeBCellLymphoma #Lymphoma #HemeOnc #MedEd
0 vue
Publié le 26/08/2026 23:54
🩸 Facts about Diffuse Large B-Cell Lymphoma:
EPCORE NHL-2, bispecific + ADC combinations, ECHELON-3, polatuzumab vedotin, and loncastuximab tesirine, including key trial results and treatment advances in relapsed/refractory disease.
#DLBCL #DiffuseLargeBCellLymphoma #Lymphoma #HemeOnc #MedEd
0 commentaire
?